Volume | 32,726 |
|
|||||
News | - | ||||||
Day High | 2.2399 | Low High |
|||||
Day Low | 2.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.10 | 2.04 | 2.2399 | 2.07 | 2.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
205 | 32,726 | $ 2.12 | $ 69,414 | - | 1.95 - 68.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:18:55 | 50 | $ 2.03 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.45M | 1.67M | - | 645k | -32.7M | -19.64 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aditxt News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.37 | 2.40 | 1.95 | 2.15 | 35,135 | -0.30 | -12.66% |
1 Month | 3.16 | 3.21 | 1.95 | 2.44 | 46,975 | -1.09 | -34.49% |
3 Months | 3.75 | 5.45 | 1.95 | 3.35 | 381,597 | -1.68 | -44.80% |
6 Months | 4.56 | 9.50 | 1.95 | 5.33 | 866,607 | -2.49 | -54.61% |
1 Year | 22.844 | 68.08 | 1.95 | 8.91 | 561,875 | -20.77 | -90.94% |
3 Years | 113.60 | 1,139.60 | 1.95 | 48.70 | 2,259,240 | -111.53 | -98.18% |
5 Years | 211.20 | 1,139.60 | 1.95 | 72.51 | 2,192,191 | -209.13 | -99.02% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |